GlassScriptPhysician profile
Stephanie A Crane
NPI 1871771469
$3,614.76
in general payments reported to CMS, 2019-2025
39 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $62.30 · 2021: $164 · 2022: $666 · 2023: $817 · 2024: $978 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,010.79 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $680.79 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $300.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $208.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $174.71 | 2022-2024 | Azstarys |
| Pfizer INC. | $165.45 | 2022-2024 | |
| Amgen INC. | $153.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $106.64 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Kowa Pharmaceuticals America, INC. | $71.51 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $55.81 | 2019-2020 | |
| Cranial Technologies, INC | $51.79 | 2019-2024 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $46.83 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $42.23 | 2021 | |
| Nestle Healthcare Nutrition INC. | $41.43 | 2021 | |
| Boston Scientific Corporation | $35.25 | 2024 | Wavewriter Alpha Prime 16 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.